عوامل خطرساز متابولیک در بیماری اسکیزوفرنی و اختلال دوقطبی: اثر کمدیکاسیون با مهارکننده های بازجذب سروتونین و ضد پریودیوتیک

The findings indicate only minor deteriorations of metabolic variables associated with treatment with an SSRI in addition to olanzapine and quetiapine, and none when combined with risperidone. These results suggest that SSRIs can be used in combination with antipsychotics, and that the possible increase in cardiovascular risk is negligible.